At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 86 enrolled
Drug / intervention
BAT7104 injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Open Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Clinical Efficacy of BAT7104 Injection in Patients With Advanced Malignant Tumors.
In Brief
A Phase 1 clinical trial evaluating BAT7104 injection for Advanced Malignant Tumor. Completed, enrolled 86 participants across 1 site.
Detailed Summary
A multi-center, open phase Ia/Ib clinical study to evaluate the safety, tolerance, pharmacokinetics and preliminary clinical efficacy of BAT7104 injection in patients with advanced malignant tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Tumor
CountriesChina
CollaboratorsSun Yat-Sen University Cancer Center
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartJan 2022
First PostedMar 2023
Primary CompletionDec 2024
TodayJul 2026
First PostedMar 14, 2023
Enrollment StartJan 20, 2022
Primary CompletionDec 11, 2024
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 3.3 years ago
Interventions
BAT7104 injectiondrug
According to the protocol, each dose group is given intravenous infusion at the rate of mg/kg, and the recommended infusion time is ≥ 60 minutes. Once every two weeks (Q2W), on the first day of each cycle.